Archives
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-11
- 2018-10
- 2018-07
-
br The HDC knockout mouse as a pathophysiological
2021-11-11
The HDC knockout mouse as a pathophysiological model of TS The implication of a hypomorphic allele of the Hdc gene as a rare cause of TS (Ercan-Sencicek et al., 2010) created a rare opportunity for the generation of a pathophysiologically grounded model of the disorder. Modeling pathophysiology o
-
An azabicyclic compound named S a a hexahydro
2021-11-11
An azabicyclic 6-Bnz-cAMP sodium salt named S 38093, (4-[3-(3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrol-2-yl)propoxy]benzamide), was introduced by Servier with H3R antagonist and inverse agonist activity (Sors et al., 2017). The compound contains all the drug-likeness criteria owing to its physi
-
br Acknowledgments The authors gratefully acknowledge the fi
2021-11-11
Acknowledgments The authors gratefully acknowledge the financial support of this study by STCU Project 6052 “Enzyme multibiosensor system for renal dysfunction diagnosis and hemodialysis control”. Furthermore, this study was supported by NASU in the frame of Scientific and Technical Program “Sens
-
br Materials and methods br Results br Discussions
2021-11-10
Materials and methods Results Discussions The treated tannery effluent (both MF and MF+RO treated) was free from most of the organic and inorganic loadings as reflected from the values of COD, BOD, total kjeldahl nitrogen (TKN) and sulfides etc. Toxicity study of the effluent (both treated
-
Concerning the molecular mechanisms underlying transcription
2021-11-10
Concerning the molecular mechanisms underlying transcriptional regulation of the GSTP1-1 gene expression we and others have characterized structural and functional properties of the human GSTP1-1 promoter. GSTP1-1 gene promoter activity is driven by a TATA-box [16] as well as Spl [16], [17], AP-1 [1
-
Studies with GSNOR knockout mice reported decreased CD cells
2021-11-10
Studies with GSNOR knockout mice reported decreased CD4+ Mifepristone and increased CD19+ cells (B-cell) in the blood [31] as well as demyelination, neurodegeneration, and neuropathic pain [29]. To understand the basis of these differences in immune function of GSNOR knockout mice and GSNO treated
-
A few methods have been
2021-11-10
A few methods have been developed to separate and prepare compounds from L. chinensis, such as silica gel column chromatography [5,6] and high-performance liquid chromatography (HPLC) [7]. Silica gel column chromatography is still used for its simple equipment and low cost. However, this method is o
-
GLP is an intestinal peptide
2021-11-10
GLP-1 is an intestinal peptide hormone that is released by the gut following ingestion of food, particularly Closantel Sodium and fats. Following its release, GLP-1 stimulates pancreatic β-cells to secrete insulin (Hirasawa et al., 2005, Covington et al., 2006). Originally, GLP-1 acted in a similar
-
VU 591 hydrochloride The DNA cleavage activity assay in the
2021-11-10
The DNA cleavage activity assay in the present study also demonstrated the DNA glycosylase activities of SMUG1, NEIL1, TDG, and NTHL1 for 5OHU paired with A. While our findings on the activities of SMUG1 and NEIL1 were consistent with the results reported from previous studies [25], [50], the activi
-
Our overall goal is to develop selective compounds
2021-11-10
Our overall goal is to develop selective compounds for low-affinity/high-capacity transporters inhibitors (i.e. OCT1–3 and PMAT), and provide the field with much needed, specific pharmacological tools to study these transporters. In our initial efforts, we synthesized halogen substituted analogs and
-
As cardiovascular disease accounts for
2021-11-10
As cardiovascular disease accounts for the majority of deaths in subjects with T2D, it is imperative that we better characterize the cardiovascular risks and benefits of the various therapies we prescribe to these individuals to control their glycemia. Indeed, the potential to identify subsets of di
-
Work in the Ruiz i Altaba lab
2021-11-10
Work in the Ruiz i Altaba lab was funded by grants from the Swiss National Science Foundation, the Ligue Suisse Contre le Cancer, the European FP7 Marie-Curie Initial Training Network HEALING, a James McDonnell Foundation 21st Century Science Initiative in Brain Cancer-Research Award and funds from
-
br Conflicts of interests br Acknowledgements We thank
2021-11-10
Conflicts of interests Acknowledgements We thank Drs. T. Tomita and T. Iwatsubo (Tokyo University, Tokyo, Japan) for anti-presenilin 1-CTF antiserum, Dr. A. Takashima (Gakushuin University, Tokyo, Japan) for anti-Pen-2 antiserum and the laboratory members for helpful comments and discussion. M
-
br The bile acid farnesoid X
2021-11-10
The “bile acid” farnesoid X receptor (FXR) The Farnesoid X Receptor (FXR) is a ligand-activated nuclear receptor belonging to the Nuclear Receptor superfamily of transcription factors exploiting various crucial functions in mammalian physiology, including reproduction, development and metabolism
-
br Financial support This work was
2021-11-10
Financial support This work was supported by Fondation pour la Recherche Médicale (Equipe labellisée, DEQ20150331724), Inserm, University of Lille, and Agence Nationale pour la Recherche (ANR-10-LBEX-46 and ANR-10-INBS-08; ProFI project, “Infrastructures Nationales en Biologie et Santé”; “Investi
16423 records 574/1095 page Previous Next First page 上5页 571572573574575 下5页 Last page